Browse articles from EyeWorld.org related to IOLs. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Phase 3 clinical program complete for epithelium-on crosslinking treatment ➤ NDA submitted for oral Stargardt disease therapy ➤ Preclinical data shared for investigational TED therapy ➤ Three new clinical programs to begin for inherited retinal diseases ➤ ASCRS news and events ➤ EyeWorld article of the week
➤ First patient dosed in Phase 3 trial evaluating cenegermin for PCED ➤ First patient dosed in Phase 3 study for Stargardt treatment ➤ First patient randomized into registrational trial for first-in-class dry eye therapy ➤ FDA clears new software for retinal imaging machine ➤ Company news ➤ ASCRS news and events ➤ EyeWorld article of the week
➤ FDA Orphan Drug and Fast Track Designations granted to investigational NK therapy ➤ DME drop study does not meet Phase 3 endpoint ➤ Phase 1b trial begins for first-in-class DME treatment ➤ ASCRS news and events ➤ EyeWorld article of the week
➤ First commercial cases of laser-based, non-incisional trabeculotomy procedure ➤ FDA grants appeal, allowing for BLA resubmission of AMD treatment ➤ Study: small-aperture IOL safe, effective for irregular corneas ➤ Company news ➤ ASCRS news and events ➤ EyeWorld article of the week
➤ 36-month results from first-in-human study with shape-changing IOL ➤ New data for recently approved EDOF IOL ➤ Company completes first-in-human robotic cataract surgery ➤ Phase 2 study approved for secondary IOL intended for low-vision patients ➤ Investigational device measures real-time intraoperative aqueous outflow ➤ FDA expands dosing on label for faricimab ➤ Company news ➤ ASCRS news and events
➤ Keep up with ASCRS Annual Meeting coverage with EyeWorld Onsite ➤ Positive topline results from Phase 3 trial for TED drug with new delivery method ➤ FDA expands dosing interval for wet AMD, DME treatment ➤ IDE granted to noninvasive bioelectric stimulation therapy for dry AMD ➤ First patients dosed in Phase 3 corneal cell therapy ➤ TED investigational treatment fails to meet primary endpoint ➤ OTC eye drop recall after FDA enforcement report cites sterility concerns ➤ ASCRS news and events
With expanding lens options in cataract surgery and an increase in combined glaucoma and cataract procedures, two ophthalmologists went into detail on when the Light Adjustable Lens (LAL, RxSight) can be a good option for glaucoma patients and considerations when choosing it.
EyeWorld spoke with two experts on the topic of when the Ks don’t align—when misalignment is clinically significant, what can be done about it, and how it impacts lens choices.
➤ FDA approves new EDOF with limited dysphotopsias ➤ Phase 1/2 12-month data for IOL-based drug delivery system ➤ Topline results from Phase 2a wet AMD study ➤ FDA grants Breakthrough Device Designation to brain implant technology ➤ FDA allows Phase 1/2 trial to begin for investigational cell therapy for familial drusen ➤ ASCRS news and events
➤ First patient treated with novel crosslinking approach for refractive error ➤ Multisociety working group established to set guidelines for modern IOL classification ➤ FDA reduces clinical trial requirement for new drugs to one pivotal trial ➤ ASCRS news and events
Get the latest ophthalmology news delivered to your inbox every Friday.